CRISPR knock-out has been successfully demonstrated for tumour-suppressor genes in brain tumour modelling [105], with potential for the same principles to be applied to a therapeutic approach for BRG1 inhibition in brain cancers where BRG1 exhibits oncogenic functions. The gene discussed is SMARCA4; the disease is brain neoplasm.